TY - JOUR T1 - Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India JF - medRxiv DO - 10.1101/2021.01.05.21249264 SP - 2021.01.05.21249264 AU - R. Cai AU - P. Novosad AU - V. Tandel AU - S. Asher AU - A. Malani Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249264.abstract N2 - There are very few estimates of the age-specific infection fatality rate (IFR) of SARS-CoV-2 in low- and middle-income countries. India reports the second highest number of SARS-CoV-2 infections in the world. We estimate age-specific IFR using data from seroprevalence surveys in Mumbai (population 12 million) and Karnataka (population 61 million), and a random sample of economically distressed migrants in Bihar with mortality followup. Among men aged 50–89, IFR is 0.12% in Karnataka (95% C.I. 0.09%–0.15%), 0.53% in Mumbai (0.52%–0.54%), and 5.64% among migrants in Bihar (0–11.16%). IFR in India is approximately twice as high for men as for women, is heterogeneous across contexts, and rises much less at older ages than in comparable studies from high income countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis paper was partially funded by Emergent Ventures Grant #466, given to A. Malani.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was not subject to an IRB/oversight body, because there was no interaction with human subjects and no privately identifiable information. Data gathered from bio-samples have been reported in separate papers, but aggregated and anonymized for use in this paper.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReplication code will be posted in a public repository on Github. The repository will include all data on demographics and COVID-19 deaths by location, seroprevalence aggregates for Mumbai and Karnataka, and mortality rates by age and gender for migrants from Bihar. We do not have permission to share seroprevalence microdata. Replication code will be provided to reconstruct all results in the paper from these data. ER -